Mechanism Hepatitis C virus NS 5 protein inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Sodium channels blockers |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Nav1.8 blockers |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Jan 2024 |
Sponsor / Collaborator |
Start Date13 Nov 2023 |
Sponsor / Collaborator |
Start Date07 Apr 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
KK-6168 ( Hepatitis C virus NS 5 protein ) | Hepatitis C More | Discontinued |
FY-504 ( Nav1.8 ) | Peripheral Nervous System Diseases More | Pending |
YD-307 ( Sodium channels ) | Neuralgia More | Pending |